BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
20 nov. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
12 nov. 2024 16h03 HE
|
AVITA Medical
AVITA Medical announces exclusive distribution agreement to expand the RECELL product platform to Australia and New Zealand.
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
12 nov. 2024 07h29 HE
|
BioStem Technologies, Inc.
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
29 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All MAC Regions
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
28 oct. 2024 13h58 HE
|
BioStem Technologies, Inc.
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
RedDress Announces ActiGraft Pro Added to WCA Formulary
24 oct. 2024 08h40 HE
|
RedDress
RedDress today announced that ActiGraft Pro has been added to the Wound Care Advantage (WCA) Formulary after a comprehensive evaluation.
Wound Care Market to Witness 3.1% CAGR by 2031 | SkyQuest Technology
17 oct. 2024 17h00 HE
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Oct. 17, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Wound Care Market will attain the value of USD 16.32 Billion by 2031, with a CAGR of 3.1% during the forecast period...
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
17 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
15 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
02 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers